| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
83,754,000 |
| Market
Cap: |
709.40(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.54 - $12.14 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 11 |
| Insider 3/6 Months : 11.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. Co.'s primary product candidate, ziftomenib, is a selective, reversible and oral small molecule inhibitor which blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene. Co.'s second product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of farnesyl transferase. Co. is evaluating tipifarnib in multiple solid tumor and hematologic indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
100,000 |
100,000 |
100,000 |
| Total Buy Value |
$0 |
$713,346 |
$713,346 |
$713,346 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
3 |
3 |
3 |
| Total Shares Sold |
104,411 |
182,469 |
208,268 |
238,993 |
| Total Sell Value |
$1,035,770 |
$1,733,781 |
$1,934,306 |
$2,283,792 |
| Total People Sold |
6 |
7 |
8 |
9 |
| Total Sell Transactions |
12 |
18 |
21 |
30 |
| End Date |
2025-10-31 |
2025-07-30 |
2025-01-29 |
2024-01-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bair Teresa Brophy |
Chief Legal Officer |
• – – |
2026-01-27 |
4 |
S |
$8.46 |
$94,828 |
D/D |
(11,208) |
226,931 |
|
- |
|
| Powl Brian T. |
Chief Commercial Officer |
• – – |
2026-01-27 |
4 |
S |
$8.46 |
$54,266 |
D/D |
(6,414) |
183,275 |
|
- |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2026-01-27 |
4 |
S |
$8.46 |
$15,339 |
D/D |
(1,813) |
153,560 |
|
- |
|
| Burrows Francis |
Chief Scientific Officer |
• – – |
2026-01-27 |
4 |
S |
$8.46 |
$11,092 |
D/D |
(1,311) |
32,424 |
|
- |
|
| Doyle Thomas James |
SVP, Finance & Accounting |
• – – |
2026-01-27 |
4 |
S |
$8.46 |
$60,426 |
D/D |
(7,142) |
145,167 |
|
- |
|
| Leoni Mollie |
Chief Medical Officer |
• – – |
2026-01-27 |
4 |
S |
$8.46 |
$69,209 |
D/D |
(8,180) |
267,274 |
|
- |
|
| Leoni Mollie |
Chief Medical Officer |
• – – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
275,454 |
|
- |
|
| Doyle Thomas James |
SVP, Finance & Accounting |
• – – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
21,250 |
152,309 |
|
- |
|
| Bair Teresa Brophy |
Chief Legal Officer |
• – – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
238,139 |
|
- |
|
| Powl Brian T. |
Chief Commercial Officer |
• – – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
189,689 |
|
- |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2026-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
155,373 |
|
- |
|
| Burrows Francis |
Chief Scientific Officer |
• – – |
2025-12-18 |
4 |
S |
$9.78 |
$231,931 |
D/D |
(23,726) |
33,735 |
|
14% |
|
| Burrows Francis |
Chief Scientific Officer |
• – – |
2025-12-18 |
4 |
OE |
$4.80 |
$168,000 |
D/D |
35,000 |
57,461 |
|
- |
|
| Doyle Thomas James |
SVP, Finance & Accounting |
• – – |
2025-11-14 |
4 |
S |
$11.18 |
$50,732 |
D/D |
(4,539) |
130,257 |
|
24% |
|
| Powl Brian T. |
Chief Commercial Officer |
• – – |
2025-11-14 |
4 |
S |
$11.18 |
$99,329 |
D/D |
(8,887) |
139,689 |
|
24% |
|
| Leoni Mollie |
Chief Medical Officer |
• – – |
2025-11-14 |
4 |
S |
$11.18 |
$173,074 |
D/D |
(15,485) |
225,454 |
|
24% |
|
| Bair Teresa Brophy |
Chief Legal Officer |
• – – |
2025-11-14 |
4 |
S |
$11.18 |
$98,401 |
D/D |
(8,804) |
188,139 |
|
24% |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2025-11-14 |
4 |
S |
$11.18 |
$77,143 |
D/D |
(6,902) |
105,373 |
|
24% |
|
| Doyle Thomas James |
SVP, Finance & Accounting |
• – – |
2025-11-13 |
4 |
A |
$0.00 |
$0 |
D/D |
24,967 |
134,796 |
|
- |
|
| Powl Brian T. |
Chief Commercial Officer |
• – – |
2025-11-13 |
4 |
A |
$0.00 |
$0 |
D/D |
48,900 |
148,576 |
|
- |
|
| Leoni Mollie |
Chief Medical Officer |
• – – |
2025-11-13 |
4 |
A |
$0.00 |
$0 |
D/D |
82,500 |
240,939 |
|
- |
|
| Bair Teresa Brophy |
Chief Legal Officer |
• – – |
2025-11-13 |
4 |
A |
$0.00 |
$0 |
D/D |
48,900 |
196,943 |
|
- |
|
| Ford Kathleen |
Chief Operating Officer |
• – – |
2025-11-13 |
4 |
A |
$0.00 |
$0 |
D/D |
48,900 |
112,275 |
|
- |
|
| Wilson Troy Edward |
President and CEO |
• • – |
2025-11-13 |
4 |
A |
$0.00 |
$0 |
D/D |
182,500 |
429,353 |
|
- |
|
| Powl Brian T. |
Chief Commercial Officer |
• – – |
2025-09-29 |
4 |
S |
$8.94 |
$79,505 |
D/D |
(8,891) |
99,676 |
|
6% |
|
154 Records found
|
|
Page 1 of 7 |
|
|
0.10 (1.17%) 
